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In this study, we found that ambroxol hydrochloride (128µg/mL) exhibits synergistic
antifungal effects in combination with fluconazole (2µg/mL) against resistant planktonic
Candida albicans (C. albicans) cells. This combination also exhibited synergistic effects
against resistant C. albicans biofilms in different stages (4, 8, and 12 h) according
to the microdilution method. In vitro data were further confirmed by the success of
this combination in treating Galleria mellonella infected by resistant C. albicans. With
respect to the synergistic mechanism, our result revealed that ambroxol hydrochloride
has an effect on the drug transporters of resistant C. albicans, increasing the uptake
and decreasing the efflux of rhodamine 6G, a fluorescent alternate of fluconazole.
This is the first study to investigate the in vitro and in vivo antifungal effects, as well
as the possible synergistic mechanism of ambroxol hydrochloride in combination with
fluconazole against resistant C. albicans. The results show the potential role for this drug
combination as a therapeutic alternative to treat resistantC. albicans and provide insights
into the development of antifungal targets and new antifungal agents.
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INTRODUCTION
In the past few decades, fungi have emerged as an important cause of severe and fatal infections,
with a >200% increase in annual fungal sepsis cases recorded in the USA (Pfaller and Diekema,
2007). C. albicans is one of the most common opportunistic pathogens in humans, and the
infections caused by this fungus are associated with a high mortality, often in excess of 30%,
due to the limited types of available antifungal agents and the emergence of drug resistance
(Wisplinghoff et al., 2004; Pfaller and Diekema, 2007). Only a few types of antifungal agents
are currently available, such as azoles, echinocandins, polyenes, and allylamines (Prasad et al.,
2016). Among them, fluconazole (FLC), one of the azoles, is the most commonly used agent to
treat infections caused by C. albicans due to its high bioavailability and low toxicity (Fiori and
Van Dijck, 2012; Han et al., 2013; Sarkar et al., 2014). However, the extensive and frequent use
of FLC has led to the development of genetically acquired drug resistance (e.g., overexpression
of drug eﬄux genes) in C. albicans and has introduced challenges in the treatment of fungal
infections. In addition, C. albicans can easily form biofilms on medical devices, which is
considered physiologically associated with the acquisition of drug resistance and results in the
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resistance of C. albicans to antifungal agents (Mathe and
Van Dijck, 2013; Zhang et al., 2013; Akbari and Kjellerup,
2015). Therefore, drug resistance in C. albicans is becoming
an increasingly important issue. Treatment approaches for
infections caused by drug-resistant C. albicans are lacking, and
patients must receive pharmacotherapy with toxic antifungals
(Chen et al., 2013). Thus, the development of improved
antifungal treatments to combat drug resistance is urgently
needed. Combination treatment of FLC with non-antifungal
agents has been one of the most successful approaches to combat
the resistance of fungi (Liu et al., 2014, 2016; Gu et al., 2016).
Utilizing synergistic drug combinations could potentially reduce
the toxicity that may occur when patients are exposed to high
doses of drugs.
Ambroxol hydrochloride (ABH) is widely used to treat
chronic obstructive pulmonary disease, chronic bronchitis,
bronchial asthma, spastic bronchitis, and bronchopulmonary
complications after chest surgery. ABH is associated with potent
expectorating action, improvement of respiratory function and
low toxicity (Malerba and Ragnoli, 2008). Furthermore, ABH
has been reported to exert antioxidant activity and relieve
inflammation by reducing the release of inflammatory cytokines
(Gillissen et al., 1997; Pfeifer et al., 1997; Gibbs et al., 1999).
The efficacy, tolerability and safety of ABH have been clinically
verified (Fischer et al., 2002; Malerba and Ragnoli, 2008; de Mey
et al., 2015). Interestingly, ABH alone at high concentrations
from 1 to 60 mg/mL has been shown to exhibit antimicrobial
effects on C. albicans, Candida parapsilosis and Pseudomonas
aeruginosa (Li et al., 2008; Pulcrano et al., 2012; Rene et al., 2014).
However, no study has investigated the combined antifungal
effects of ABH with FLC.
The present study was designed to determine the potential
antifungal effects of FLC and ABH against Candida spp. and the
effects of this drug combination on resistant C. albicans biofilms
in different stages in vitro. A recently established infectionmodel,
Galleria mellonella (G. mellonella), was used to determine the
antifungal effects of this drug combination in vivo. The potential
synergistic mechanism associated with this drug combination
was also detected by determining the activity of drug uptake and
eﬄux of resistant C. albicans.
MATERIALS AND METHODS
Isolates and Growth Media
Twelve Candida spp. isolates with different susceptibilities were
used in this study, including four C. albicans isolates (CA4,
CA8, CA10, and CA16), four Candida glabrata isolates (CG1,
CG2, CG3, and CG8) and four Candida krusei isolates (CK2,
CK3, CK9, and CK10). Both C. glabrata and C. krusei are non-
C. albicans types. Each Candida spp. included two resistant and
two susceptible isolates, as shown in Table 1. Candida albicans
ATCC 10231 was used as a quality control isolate. All isolates
Abbreviations: FLC, Fluconazole; ABH, Ambroxol hydrochloride; CA,
C. albicans; YPD, Yeast–peptone–dextrose; G. Mellonella, Galleria mellonella;
PAS, Periodic acid Schiff reagent; Rh6G, Rhodamine 6G; MFI, Mean fluorescent
intensity.
TABLE 1 | Drug interactions of FLC and ABH against Candida spp. in vitro.
Drugs Isolatesa MIC (µg/mL)b FICI model
FLC FLCcomb ABH ABHcomb FICI
c Interpretation
CA4 (S) 1 0.0313 >512 512 1.031 No interaction
CA8 (S) 2 0.25 >512 512 1.125 No interaction
CA10 (R) >512 2 512 128 0.254 Synergism
CA16 (R) >512 2 512 128 0.254 Synergism
CG1 (S) 16 0.25 512 512 1.016 No interaction
FLC+
ABH
CG8 (S) 32 16 512 256 1.000 No interaction
CG2 (R) 128 32 512 256 0.750 No interaction
CG3 (R) 128 0.5 512 512 1.004 No interaction
CK2 (S) 16 8 512 512 1.500 No interaction
CK3 (S) 32 2 512 512 1.063 No interaction
CK9 (R) 64 32 512 256 1.000 No interaction
CK10 (R) 256 32 1024 512 0.625 No interaction
aTwelve isolates with different susceptibilities involved three Candida spp. CA, Candida
albicans; CG, Candida glabrata; CK, Candida krusei.
bMICs denote the MIC80 of each drug alone or in combination (comb) against the isolates
and are shown as the median of three independent experiments; FLC, fluconazole; ABH,
ambroxol hydrochloride; S, susceptible; R, resistant.
cThe FICI value is the median of three independent experiments; FICI≤ 0.5 for synergism,
FICI > 4.0 for antagonism and 0.5 < FICI ≤ 4.0 for no interaction.
were refreshed from the frozen storage at −80◦C and inoculated
twice onto yeast–peptone–dextrose (YPD) solid medium (2%
agar, 2% peptone, 2% glucose, and 1% yeast extract) for 18 h at
35◦C. YPD liquid medium consisted of 2% peptone, 2% glucose,
and 1% yeast extract. Egg yolk agar medium consisted of 5%
NaCl, 1% peptone, 3% glucose, 0.0006%CaCl2, 10% egg yolk, and
2% agar.
Drugs and G. mellonella Larvae
All drugs, including FLC, ABH, and ampicillin, were purchased
from Dalian Meilun Biotech Co., Ltd. (Dalian, China). Stock
solutions of FLC (2,560µg/mL), ABH (5,120µg/mL), and
ampicillin (2,560µg/mL) were prepared in sterile distilled water
and stored at −20◦C until use. The larvae of G. mellonella
were purchased from Tianjin Huiyude Biotech Co., Ltd. (Tianjin,
China).
Determination of In vitro Antifungal Effects
Determination of the Minimal Inhibitory
Concentration (MIC) of Planktonic Cells
The MICs of FLC and ABH against 12 Candida spp. isolates
were determined with a broth microdilution method using two-
fold serial dilutions in RPMI 1640 medium as described by the
Clinical and Laboratory Standards Institute method M27-A3
document. The tests were performed in 96-well flat-bottomed
microtiter plates. Plates were incubated at 35◦C for 24 h. After
incubation, an XTT reduction assay was used to determine the
MIC, which was read at the lowest concentration that showed
80% inhibition of growth compared with that of the drug-free
control (Li et al., 2015). The fractional inhibitory concentration
index (FICI) model was used to interpret the antifungal effects
on planktonic cells In vitro. The FICI model is as follows
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(Guo et al., 2008): FICI = FICFLC+ FICABH = (MIC80 of FLC
in combination/MIC80 of FLC alone) + (MIC80 of ABH in
combination/MIC80 of ABH alone). The results were defined as
FICI ≤ 0.5 for synergism, FICI > 4.0 for antagonism and 0.5 <
FICI ≤ 4.0 for no interaction (Odds, 2003).
Determination of Sessile MIC (SMIC) of C. albicans
Biofilms
The SMICs of FLC and ABH against resistant C. albicans biofilms
were tested as described previously (Ramage and Lopez-Ribot,
2005). As described in a previous study, 4, 8, and 12 h biofilms
of CA10 were formed in 96-well flat-bottomed microtiter plates
(Gu et al., 2016). Then, drugs were added to the plates and
the plates were incubated for an additional 24 h at 37◦C. XTT
reduction assays were performed to determine the SMICs. SMICs
were defined as the lowest antifungal concentrations where
there was an 80% (SMIC80) reduction in the XTT-colorimetric
readings in comparison to the drug-free control. Colorimetric
changes were measured at 492 nm with a microtiter plate reader
(SpectraMax190, USA). The FICI model was used to interpret the
antifungal effects for biofilms as described above.
Determination of In vivo Antifungal Effects
Batches ofG. mellonella larvae in the final instar stage were stored
in the dark at 25◦C, and larvae weighing approximately 250mg
were selected for use in the experiments. The doses (1.6µg/larva
for FLC and 3.2µg/larva for ABH) used to treat larvae mimicked
those used to treat humans. Each group contained 16 randomly
chosen larvae. The preliminary steps for each in vivo experiment
were the same. In detail, larvae were inoculated with 10µL of
the cell suspension (5× 108 CFU/mL) into the prolegs using 50-
µL syringes (Shanghai Gaoge Biotech Co., Ltd. Shanghai, China).
After 2 h, treatment with the drugs separately or in combination
was administered using the 50-µL syringes, while a control group
of infected larvae received PBS only.
For survival assays, a preliminary experiment was first carried
out to test whether there are harmful effects of PBS and drugs
on the uninfected G. mellonella larvae. Only 10µL of PBS,
FLC, ABH, and drug combination were inoculated into the
G.mellonella larvae in each group, without treatment of the CA10
cell suspension. For the formal survival assay, the larvae were
pretreated as described above. The number of surviving larvae
in each group was recorded every day for up to 4 days. Survival
data were plotted according to the Kaplan-Meier method using
the Statistical Product and Service Solutions 19 software.
For determination of the fungal burden, the larvae were
pretreated as described above. Three larvae from each group were
randomly culled every day over 4 days. C. albicans burdens were
determined by inoculating dilutions of the homogenized larvae
onto YPD solid medium plates as previously described (Gu et al.,
2016). These plates were incubated overnight at 35◦C. Fungal
burden data were recorded using a CFU counting method.
For histological study, the larvae were pretreated as described
above. One infected larva from each group was randomly selected
at 3 days post-infection and cut into 7-µm tissue slices. The
tissue slices of infected larvae were stained with Periodic acid
Schiff reagent (PAS) and observed under an Olympus FSX100
fluorescence microscope with 4.2× 10 objectives.
Synergistic Mechanism Explorations
Uptake and Efflux of Rhodamine 6G (Rh6G)
CA10 cells at a concentration of 1 × 106 CFU/mL were allowed
to grow aerobically in 5 mL YPD liquid medium at 35◦C for 18 h.
The cells were harvested, washed twice with glucose-free PBS,
and resuspended in the same buffer to obtain a concentration of
1 × 107 CFU/mL. The cells were then de-energized for 1 h in
glucose-free PBS. The de-energized cells were harvested, washed,
and then resuspended again to obtain a concentration of 1× 107
CFU/mL.
To assess the uptake of Rh6G, Rh6G, and ABH were added
to the exhausted cells at a final concentration of 10µM and
128µg/mL, respectively. Cells without ABH treatment served as
the control. Samples were incubated for 50 min at 35◦C and then
washed with glucose-free PBS. A BD FACSAria II flow cytometer
(Becton Dickinson, USA) with excitation at 488 nm and emission
at 530 nm was used to determine the mean fluorescent intensity
(MFI) of each sample at specific time intervals (0, 10, 20, 30, 40,
and 50 min).
To assess the eﬄux of Rh6G, Rh6Gwas added to the exhausted
cells at a final concentration of 10µM. Cells were then washed
with glucose-free PBS, and ABH was added to the cells at a
final concentration of 128µg/mL. Cells without ABH treatment
served as the control. Samples were incubated for 50 min at 35◦C
and then washed with glucose-free PBS. After the addition of 5
mL of 5% glucose-PBS to each sample, the MFI was immediately
determined using the flow cytometer as described above at
specific time intervals (0, 30, 60, 90, 120, and 150 min).
RESULTS
ABH Combined with FLC Exhibited
Synergistic Effects on Planktonic Cells of
Resistant C. albicans In vitro
To assess the in vitro interactions between FLC and ABH
against Candida spp., the data were obtained using the broth
microdilutionmethod and interpreted using the FICI model. The
MICs of FLC and ABH alone and in combination against the 12
Candida spp. isolates in vitro are listed in Table 1. The results
show that ABH combined with FLC has synergistic effects on
resistant C. albicans in vitro. The addition of ABH resulted in a
decrease in the MIC of FLC for resistant C. albicans CA10 and
CA16 from >512 to 2µg/mL, while both of the FICI values were
lower than 0.5 (Table 1, Table S1). However, no synergism was
observed when this drug combination was used to inhibit two
susceptible C. albicans isolates and eight non-C. albicans isolates
in vitro, with the FICIs distributed from 0.625 to 1.500 (Table 1).
ABH Combined with FLC Exhibited
Synergistic Effects against Biofilms in
Different Stages
To assess interactions between FLC and ABH against C. albicans
biofilms at different stages, the data obtained by the broth
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microdilution method were analyzed using the FICI model
described above. The results for the tested drugs alone and in
combination in biofilms of resistant C. albicans at 4, 8, and 12 h
are summarized in Table 2. There was close agreement between
these two models for the FLC-ABH combination treatment on
C. albicans biofilms. As shown in Table 2, ABH combined with
FLC showed synergistic antifungal effects against 4, 8, and 12 h
biofilms, all with FICI = 0.252. In addition, the MIC of ABH
for 12 h biofilms (256µg/mL) was higher than that of 4 and 8
h biofilms (128µg/mL).
ABH Combined with FLC Showed
Synergistic Effects against Resistant
C. albicans In vivo
Following the identification of the synergism between FLC and
ABH in vitro, experiments were designed to identify whether this
effect would be replicated in vivo. In the preliminary survival
assay, all uninfected G. mellonella larvae in four groups (PBS,
FLC, ABH, and drug combination) were alive after 4 days,
indicating that PBS and the drugs have no harmful effect on
G. mellonella. The effect of the drugs alone or in combination
on the survival rates, fungal burden and histopathology of
infected larvae is shown in Figures 1–3, respectively. When used
alone, the drugs, FLC and ABH had no significant effect on
the survival rates of infected larvae. However, their combination
significantly improved the survival rates, confirming the efficacy
of this drug combination in vivo (Figure 1). Encouragingly, the
combination of FLC and ABH resulted in a greater reduction
in fungal burden compared to the control and individual drug
groups, as shown by the slower proliferation of C. albicans in the
group receiving the drug combination over 4 days (Figure 2).
Slices of infected larvae in four groups revealed a significant
decrease in the number of melanized nodules in larvae treated
with this drug combination, compared to no drug or larvae
treated with individual drugs (Figure 3). The histopathology
results are in agreement with the survival rates and fungal
burden experiments, which further confirms the synergistic
effects of FLC and ABH combination against resistant C. albicans
in vivo.
TABLE 2 | Synergistic effects of FLC alone and in combination with ABH
against biofilms of resistant C. albicans.
Time (h)a SMIC(µg/mL)b FICI model
FLC FLCcomb ABH ABHcomb FICI
c Interpretation
4 >1024 2 512 128 0.252 Synergism
8 >1024 2 1024 256 0.252 Synergism
12 >1024 2 1024 256 0.252 Synergism
aTime indicates the incubation period of biofilm formation.
bSMICs denote the SMIC80 of each drug alone or in combination (comb) against
the biofilms and are shown as the median of three independent experiments. FLC,
fluconazole; ABH, ambroxol hydrochloride.
cThe FICI value is the median of three independent experiments; FICI≤ 0.5 for synergism,
FICI > 4.0 for antagonism and 0.5 < FICI ≤ 4.0 for no interaction.
ABH Inhibited the Activity of Drug
Transporters of Resistant C. albicans
Both Rh6G and FLC are substrates of drug transporters in
C. albicans. Rh6G was used as the alternate for FLC in the present
study. We measured the uptake and eﬄux of Rh6G in resistant
C. albicans in the absence and presence of ABH. Intracellular
Rh6G uptake in the ABH-treated group increased over time,
and that in the ABH group increased faster than that in the
control group (Figure 4A). Cells treated with ABH pumped out
lower concentrations of Rh6G than cells without drug treatment.
FIGURE 1 | Effect of FLC alone or in combination with ABH on the
survival of infected G. mellonella over 4 days. The concentration of yeast
cells was 5 × 106 CFU/larva. Treatments consisted of PBS, FLC (1.6µg/larva)
alone, ABH (3.2µg/larva) alone, or a combination of FLC (1.6µg/larva) with
ABH (3.2µg/larva). The Statistical Product and Service Solutions 20 software
was used to analyze the data. The experiments were performed three times on
different days.
FIGURE 2 | Effect of FLC alone or in combination with ABH on the
fungal burden of infected G. mellonella over 4 days. The concentration of
yeast cells was 5 × 106 CFU/larva. Treatments consisted of PBS, FLC
(1.6µg/larva) alone, ABH (1.6µg/larva) alone, or a combination of FLC
(1.6µg/larva) with ABH (1.6µg/larva). For clarity, data for the treatment with
ABH are not shown because the data closely followed those of the control
group. GraphPad Prism 6 software was used to analyze the data. The
experiments were performed three times on different days.
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FIGURE 3 | Effect of FLC alone or in combination with ABH on the histopathology of infected G. mellonella at day 2 post-infection. The concentration of
yeast cells was 5 × 106 CFU/larva. Treatments consisted of PBS (A–C), FLC (1.6µg/larva) alone (D–F), ABH (1.6µg/larva) alone (G–I), or a combination (J–L) of FLC
(1.6µg/larva) with ABH (1.6µg/larva). Melanized nodules consisted of mixtures of yeast cells and filaments. Bar = 200µm. The experiments were performed three
times on different days.
This finding was evident by the sharp drop in the measured
intracellular concentrations of Rh6G in the ABH-treated group
(Figure 4B). Our results revealed that ABH can increase the
uptake and decrease the eﬄux of rhodamine 6G.
DISCUSSION
In this study, we first examined the effects of ABH combined
with FLC against planktonic Candida spp. cells with different
susceptibility and biofilms of resistant C. albicans in different
stages. Our results showed that the combination of FLC at a
low concentration (2µg/mL) with ABH at a concentration of
128µg/mL exerts synergistic effects against resistant C. albicans
only, with no synergism on susceptible C. albicans and
non-C. albicans. ABH combined with FLC also showed
synergistic antifungal effects against 4, 8, and 12 h biofilms of
resistant C. albicans. These findings indicate that ABH shows
a potent antifungal effect against the planktonic cells and
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FIGURE 4 | The effect of ABH on the (A) uptake and (B) efflux of Rh6G in
resistant C. albicans. The uptake and efflux of Rh6G in the absence and
presence of ABH (128µg/mL) were determined by a flow cytometer. Ten
thousand events were counted for each sample at specific time intervals. MFIs
represent the intracellular Rh6G in C. albicans. GraphPad Prism 6 software
was used to analyze the data. The experiments were performed three times on
different days.
biofilms of FLC-resistant C. albicans in vitro when combined
with FLC.
Although mouse models are considered a standard model to
investigate fungal pathogenesis, their disadvantages, such as cost,
logistical challenges, and the fact that they are time-consuming
and ethically delicate, have limited their application for in vivo
experimentation (Amorim-Vaz et al., 2015). Therefore, a number
of simple insect models have recently been developed for use
with fungal pathogens. For example, G. mellonella has been
increasingly used to study fungal virulence and the antifungal
activity of drug combinations (Mylonakis et al., 2005; Vu and
Gelli, 2010). In the present study, treatment of G. mellonella
larvae infected by C. albicans with a combination of FLC and
ABH exhibited greater efficacy than FLC or ABH monotherapy,
which was in accordance with the synergistic antifungal effects of
this combination In vitro. In addition, this study demonstrated
the utility of the G. mellonella larva model as an inexpensive,
rapid in vivo model to prescreen potential novel antifungal
therapies prior to more extensive mammalian animal models.
Although, the concentration of ABH required to induced the
in vivo effects may be higher than the usual doses that ABH
achieves in humans, high doses of ABH are widely used in clinics,
and a large number of clinical trials have proven that treatment
with high doses of ABH (more than 15 mg/kg or 1,000 mg/day)
appears to improve the condition of patients with acute or mild
respiratory distress syndrome and acute lung injury (Wu et al.,
2014). Therefore, the ABH concentration used in this study still
has the potential to be used clinically.
Azole-resistant isolates commonly display reduced
intracellular accumulation of antifungal agents due to their over-
expression of drug transport pumps (Prasad and Rawal, 2014).
Two main classes of drug transport pumps are responsible for
the development of antifungal resistance: ATP-binding cassette
transporters and major facilitator superfamily transporters
(Holmes et al., 2016). Considering the importance of major
antifungal transport pumps, one focus of recent research has
been to understand the relationship between this synergism
and drug transport pumps. Functional activities of drug
transport pumps have traditionally been assayed with Rh6G, a
known fluorescent substrate of several drug transport pumps
responsible for multidrug resistance in yeasts and a FLC alternate
(Ahmad et al., 2013). We employed this Rh6G-based assay to
determine whether the synergistic effects were correlated with
the inhibition of drug transport pumps. ABH was found to
significantly increase the uptake of Rh6G and decrease the
eﬄux of Rh6G, indicating that ABH improves the susceptibility
of resistant C. albicans to FLC by increasing the intracellular
concentration of FLC. Inhibiting the effects on drug transport
pumps may be one of the synergism mechanisms of ABH and
FLC in combination. Other potent mechanisms need to be
further investigated.
CONCLUSION
We suggest that combinations of antifungal drugs with other,
non-antifungal drugs, could be used as a useful approach for
overcoming drug resistance inC. albicans. In this study, we found
that combined FLC and ABH treatment results in synergistic
effects against FLC-resistant C. albicans in vitro and in vivo.
In addition, this combination also exhibited synergistic effects
against resistant C. albicans biofilms in different stages. When
looking for the mechanism of action of this drug combination,
we could not rely on any known mechanism of ABH against
C. albicans. Therefore, we first assayed the possibility that
ABH acts on the most common FLC resistance mechanism
in C. albicans, namely changes in drug uptake and eﬄux.
Remarkably, we found that ABH can increase the uptake and
decrease the eﬄux of a test compound, presumably by inhibiting
drug transporters. This leads us to suggest that the synergy
of ABH with FLC on drug-resistant C. albicans results from
an increase in intracellular FLC concentration. Our results are
thus the first to show that ABH, in combination with FLC,
can be exploited to reverse the drug resistance of C. albicans.
Therapeutic combination of ABHwith FLCmay constitute a new
alternative in the treatment of infections by resistant C. albicans.
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